Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients.
dc.contributor.author | Saxena, Anita | en_US |
dc.date.accessioned | 2007-07-08 | en_US |
dc.date.accessioned | 2009-05-27T04:29:09Z | |
dc.date.available | 2007-07-08 | en_US |
dc.date.available | 2009-05-27T04:29:09Z | |
dc.date.issued | 2007-07-08 | en_US |
dc.identifier.citation | Saxena A. Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients. Indian Heart Journal. 2007 Jul-Aug; 59(4): 299-301 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/5797 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://indianheartjournal.com | en_US |
dc.subject.mesh | Carbolines --therapeutic use | en_US |
dc.subject.mesh | Disease Progression | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypertension, Pulmonary --drug therapy | en_US |
dc.subject.mesh | India --epidemiology | en_US |
dc.subject.mesh | Phosphodiesterase Inhibitors --therapeutic use | en_US |
dc.subject.mesh | Piperazines --therapeutic use | en_US |
dc.subject.mesh | Purines --therapeutic use | en_US |
dc.subject.mesh | Sulfones --therapeutic use | en_US |
dc.title | Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients. | en_US |
dc.type | Comment | en_US |
dc.type | Editorial | en_US |
Files
License bundle
1 - 1 of 1